We first attempted to delete the IPO7 gene from the EBV-negative 293T cell line, from an EBV-positive B-cell line, 721, and from an EBV-positive gastric carcinoma cell line, SNU-719 using CRISPR/Cas9. This evidence concerns the gene IPO7 and gastric carcinoma.